Premium
NEW CHOICES FOR PATIENTS NEEDING KIDNEY TRANSPLANTATION ACROSS ANTIBODY BARRIERS
Author(s) -
Higgins Rob,
Hathaway Mark,
Lowe David,
Zehnder Daniel,
Krishnan Nithya,
Hamer Rizwan,
Briggs David
Publication year - 2008
Publication title -
journal of renal care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.381
H-Index - 27
eISSN - 1755-6686
pISSN - 1755-6678
DOI - 10.1111/j.1755-6686.2008.00025.x
Subject(s) - medicine , abo blood group system , transplantation , antibody , immunology , human leukocyte antigen , kidney transplantation , antigen
SUMMARY Antibodies in the blood of a kidney transplant recipient can provide a barrier to transplantation, which is additional to the usual possibility of cellular rejection. The antibodies most frequently encountered are ABO (blood group) and human leucocyte antigen (HLA) (tissue‐type) antibodies. About 250 living donor transplants each year in the United Kingdom have been stopped because of an antibody barrier. It is now possible to offer a choice of treatment modalities to these people, including exchange transplantation and antibody‐incompatible transplantation. It is likely that both schemes will complement each other and both are available in the United Kingdom.